PCI Pharma Services Expands Global Manufacturing Network with $1B+ Investment in San Diego
Introduction
PCI Pharma Services has announced an investment programme exceeding $1 billion across its US and European operations to strengthen sterile fill-finish and advanced drug delivery capabilities.
A key part of this plan is a $100 million expansion at its San Diego campus, aimed at enhancing capacity and supporting end-to-end pharmaceutical manufacturing.
Features
The San Diego site will add a high-speed isolator filling line for ready-to-use prefilled syringes and cartridges, significantly increasing production capacity.
The facility already supports large-scale aseptic filling and complex formulations, including biologics and highly potent products.
In Bedford, New Hampshire, PCI is commissioning a GMP-ready isolator vial and lyophilisation line capable of producing up to 300,000 vials per batch, alongside a dedicated high-potent sterile fill-finish line.
Both Bedford and San Diego will feature advanced automated visual inspection systems to ensure quality and compliance.
Further expansion includes drug-device combination assembly in Philadelphia and Rockford, where new autoinjector lines will raise capacity to over 250 million units annually.
Development Centres of Excellence in Bedford and León, Spain, will support formulation and analytical services.
The San Diego project is expected to complete in the first half of 2028, with other expansions becoming operational between 2026 and 2027.
Specifications
| Name | PCI Pharma Services |
| Budget | $1 billion |
| Type | Expansion |
| Year of completion | 2028 |
